Health
This Small-Cap Cancer Technology Company Could Pop With the Right Play
Let's look at a strategy for Cardiff Oncology, whose shares got snagged in the biotech selloff in early 2022.
I'm Giving Dynavax Another Shot -- a Booster Shot
Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
My 2022 Pick Should Keep You (and Your Portfolio) Well Cared For
Here's why I'm going with AMN Healthcare for the remainder of the year.
More Big Deals for Health Care Eyed in 2022
As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Will Clover Health Investments Turn Around?
Let's take a look at 2 charts.
This Dividend Stock Might Be Just What the Doctor Ordered
Perrigo hit some bumps, but it offers deep value and dividend growth.
Jim Cramer: Looking for Gold? Go With Science
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Time to Check Out Ebix
EBIX offers extensive potential gains while downside appears small.
Cannabis Companies Eyeing How Plant Could Help Autism Symptoms
After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.